



## ASX Announcement

# Phase II Bisantrene Trial Recruitment Completed

---

**18 March 2020** – Race Oncology Limited (“Race”) is pleased to announce that the Bisantrene Phase II trial at the Sheba Medical Center in Israel (“Sheba”) has completed patient recruitment.

The first patient in the trial was treated in July 2019 (see ASX announcement 25<sup>th</sup> July 2019) so the trial finished recruitment in 8 months. While early recruitment completion is not indicative of the success or failure of the trial, it should be noted that this investigator initiated trial was an open label study where both the clinicians and patients were aware of the earlier patient outcomes.

Final payment has been made to Sheba by Race and Race now awaits receipt of the report on the trial outcomes. Race will advise the market of the trial outcomes once the report is provided.

### About the Trial

The Phase II trial, led by Professor Arnon Nagler and titled “Bisantrene for relapsed/refractory AML” (clinicaltrials.gov identifier: NCT03820908) aimed to generate clinical remissions (CR) in patients with AML, who are resistant to other therapy (refractory), have relapsed after previous therapy, or cannot receive further anthracycline treatment. The trial was expected to recruit 12 adult subjects over 12 months and report CR and a range of secondary endpoints, including leukaemia free survival (LFS), and overall survival (OS). All patients received Bisantrene at 250mg/m<sup>2</sup>/day for 7 days, in conjunction with conventional supportive care. In the event of a CR, patients are to receive a 3-day consolidation course of Bisantrene also at 250mg/m<sup>2</sup>/day.

- ENDS -

### About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian cancers.

Release authorised by:

Peter Molloy, Managing Director

[plmolloy@raceoncology.com](mailto:plmolloy@raceoncology.com)

Media contact:

Heidi Cuthbert

+61 411 272 366

[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)